Anti-Sm and anti-RNP antibodies

Among anti-nuclear antibodies, anti-Sm and anti-RNP antibodies are of the utmost importance in clinical practice. Anti-Sm antibodies are directed against 7 proteins (B/B′, D1, D2, D3, E, F, G) that constitute the common core of U1, U2, U4 and U5 small nuclear ribonucleoprotein (snRNP) particles; B/B...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Autoimmunity (Chur, Switzerland) Switzerland), 2005-02, Vol.38 (1), p.47-54
Hauptverfasser: Migliorini, P., Baldini, C., Rocchi, V., Bombardieri, S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 54
container_issue 1
container_start_page 47
container_title Autoimmunity (Chur, Switzerland)
container_volume 38
creator Migliorini, P.
Baldini, C.
Rocchi, V.
Bombardieri, S.
description Among anti-nuclear antibodies, anti-Sm and anti-RNP antibodies are of the utmost importance in clinical practice. Anti-Sm antibodies are directed against 7 proteins (B/B′, D1, D2, D3, E, F, G) that constitute the common core of U1, U2, U4 and U5 small nuclear ribonucleoprotein (snRNP) particles; B/B′, D1 and D3 are more frequently targeted. Anti-RNP antibodies react with proteins (70 Kd, A, C) that are associated with U1 RNA and form U1snRNP. Anti-Sm and anti-RNP antibodies are directed towards both discontinuous and linear epitopes which are either contained in the protein sequence or are post-translationally modified. The assays to detect anti-Sm and anti-RNP antibodies are counterimmunoelectrophoresis (CIE), immunoblot, and ELISA, based on purified or recombinant proteins or synthetic peptides. Anti-Sm antibodies are detectable in a percentage of SLE patients comprised between 5 and 30%; they are more prevalent in blacks and because of their high specificity for SLE have been included in the serological criteria for diagnosing the disease. Anti-RNP are detectable in 25-47% of SLE patients; high titers of anti-RNP antibodies are diagnostic of mixed connective tissue disorder (MCTD). The measurement of anti-Sm and anti-RNP antibodies is more important in the diagnosis of SLE than in the follow-up of patients. However, anti-RNP antibodies are more prevalent in patients with Raynaud's phenomenon and are associated with milder renal involvement. On the contrary, anti-Sm antibodies are associated with the severity and the activity of renal involvement. The specificity of anti-Sm antibodies, together with epidemiological data, suggest that Epstein-Barr virus infection has the potential to induce anti-Sm antibodies by molecular mimicry. Anti-nuclear antibodies, a hallmark of the systemic autoimmune diseases, include several populations of antibodies with different specificities. Among them, anti-Sm and anti-RNP antibodies are of the utmost importance in clinical practice; in research, the study of the mechanisms inducing their production has opened up new perspectives and helped to elucidate the pathogenesis of autoimmune disorders.
doi_str_mv 10.1080/08916930400022715
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_15804705</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17810603</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435t-6dc56fc09cd55f0f4d7e45ac02e11a6fc8876accbfc20db3a0df11dbfc802ffa3</originalsourceid><addsrcrecordid>eNqFkFtLAzEQhYMotlZ_gC_qk2-rk90km0VfSvEGouIFfAvZXOiW3U1NdpH-e1NbEBHqwzAzzHcOw0HoEMMZBg7nwAvMigwIAKRpjukWGmIGecJJ-r6Nhst7EgEyQHshzJZUzsguGmDKgeRAh-h43HZV8tKcyFbHivPzw9P3UDpdmbCPdqysgzlY9xF6u756ndwm9483d5PxfaJIRruEaUWZVVAoTakFS3RuCJUKUoOxjBfOcyaVKq1KQZeZBG0x1nHlkForsxE6XfnOvfvoTehEUwVl6lq2xvVBsJwVjKX8XxDnHAODLIJ4BSrvQvDGirmvGukXAoNYxif-xBc1R2vzvmyM_lGs84rA5QqoWut8Iz-dr7Xo5KJ23nrZqiqIbJP_xS_51Mi6myrpjZi53rcx4Q3ffQF6GY5g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17810603</pqid></control><display><type>article</type><title>Anti-Sm and anti-RNP antibodies</title><source>MEDLINE</source><source>Taylor &amp; Francis Journals Complete</source><creator>Migliorini, P. ; Baldini, C. ; Rocchi, V. ; Bombardieri, S.</creator><creatorcontrib>Migliorini, P. ; Baldini, C. ; Rocchi, V. ; Bombardieri, S.</creatorcontrib><description>Among anti-nuclear antibodies, anti-Sm and anti-RNP antibodies are of the utmost importance in clinical practice. Anti-Sm antibodies are directed against 7 proteins (B/B′, D1, D2, D3, E, F, G) that constitute the common core of U1, U2, U4 and U5 small nuclear ribonucleoprotein (snRNP) particles; B/B′, D1 and D3 are more frequently targeted. Anti-RNP antibodies react with proteins (70 Kd, A, C) that are associated with U1 RNA and form U1snRNP. Anti-Sm and anti-RNP antibodies are directed towards both discontinuous and linear epitopes which are either contained in the protein sequence or are post-translationally modified. The assays to detect anti-Sm and anti-RNP antibodies are counterimmunoelectrophoresis (CIE), immunoblot, and ELISA, based on purified or recombinant proteins or synthetic peptides. Anti-Sm antibodies are detectable in a percentage of SLE patients comprised between 5 and 30%; they are more prevalent in blacks and because of their high specificity for SLE have been included in the serological criteria for diagnosing the disease. Anti-RNP are detectable in 25-47% of SLE patients; high titers of anti-RNP antibodies are diagnostic of mixed connective tissue disorder (MCTD). The measurement of anti-Sm and anti-RNP antibodies is more important in the diagnosis of SLE than in the follow-up of patients. However, anti-RNP antibodies are more prevalent in patients with Raynaud's phenomenon and are associated with milder renal involvement. On the contrary, anti-Sm antibodies are associated with the severity and the activity of renal involvement. The specificity of anti-Sm antibodies, together with epidemiological data, suggest that Epstein-Barr virus infection has the potential to induce anti-Sm antibodies by molecular mimicry. Anti-nuclear antibodies, a hallmark of the systemic autoimmune diseases, include several populations of antibodies with different specificities. Among them, anti-Sm and anti-RNP antibodies are of the utmost importance in clinical practice; in research, the study of the mechanisms inducing their production has opened up new perspectives and helped to elucidate the pathogenesis of autoimmune disorders.</description><identifier>ISSN: 0891-6934</identifier><identifier>EISSN: 1607-842X</identifier><identifier>DOI: 10.1080/08916930400022715</identifier><identifier>PMID: 15804705</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Amino Acid Sequence ; anti-RNP ; Anti-Sm ; Antibodies, Antinuclear - analysis ; Antibodies, Antinuclear - biosynthesis ; Antibody Specificity ; autoantibodies ; Autoantigens ; Epstein-Barr virus ; Humans ; Immunoassay ; Lupus Erythematosus, Systemic - immunology ; Lupus Nephritis - immunology ; Molecular Sequence Data ; Ribonucleoproteins, Small Nuclear - chemistry ; Ribonucleoproteins, Small Nuclear - genetics ; Ribonucleoproteins, Small Nuclear - immunology ; snRNP Core Proteins ; systemic lupus</subject><ispartof>Autoimmunity (Chur, Switzerland), 2005-02, Vol.38 (1), p.47-54</ispartof><rights>2005 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435t-6dc56fc09cd55f0f4d7e45ac02e11a6fc8876accbfc20db3a0df11dbfc802ffa3</citedby><cites>FETCH-LOGICAL-c435t-6dc56fc09cd55f0f4d7e45ac02e11a6fc8876accbfc20db3a0df11dbfc802ffa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/08916930400022715$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/08916930400022715$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,59647,60436,61221,61402</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15804705$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Migliorini, P.</creatorcontrib><creatorcontrib>Baldini, C.</creatorcontrib><creatorcontrib>Rocchi, V.</creatorcontrib><creatorcontrib>Bombardieri, S.</creatorcontrib><title>Anti-Sm and anti-RNP antibodies</title><title>Autoimmunity (Chur, Switzerland)</title><addtitle>Autoimmunity</addtitle><description>Among anti-nuclear antibodies, anti-Sm and anti-RNP antibodies are of the utmost importance in clinical practice. Anti-Sm antibodies are directed against 7 proteins (B/B′, D1, D2, D3, E, F, G) that constitute the common core of U1, U2, U4 and U5 small nuclear ribonucleoprotein (snRNP) particles; B/B′, D1 and D3 are more frequently targeted. Anti-RNP antibodies react with proteins (70 Kd, A, C) that are associated with U1 RNA and form U1snRNP. Anti-Sm and anti-RNP antibodies are directed towards both discontinuous and linear epitopes which are either contained in the protein sequence or are post-translationally modified. The assays to detect anti-Sm and anti-RNP antibodies are counterimmunoelectrophoresis (CIE), immunoblot, and ELISA, based on purified or recombinant proteins or synthetic peptides. Anti-Sm antibodies are detectable in a percentage of SLE patients comprised between 5 and 30%; they are more prevalent in blacks and because of their high specificity for SLE have been included in the serological criteria for diagnosing the disease. Anti-RNP are detectable in 25-47% of SLE patients; high titers of anti-RNP antibodies are diagnostic of mixed connective tissue disorder (MCTD). The measurement of anti-Sm and anti-RNP antibodies is more important in the diagnosis of SLE than in the follow-up of patients. However, anti-RNP antibodies are more prevalent in patients with Raynaud's phenomenon and are associated with milder renal involvement. On the contrary, anti-Sm antibodies are associated with the severity and the activity of renal involvement. The specificity of anti-Sm antibodies, together with epidemiological data, suggest that Epstein-Barr virus infection has the potential to induce anti-Sm antibodies by molecular mimicry. Anti-nuclear antibodies, a hallmark of the systemic autoimmune diseases, include several populations of antibodies with different specificities. Among them, anti-Sm and anti-RNP antibodies are of the utmost importance in clinical practice; in research, the study of the mechanisms inducing their production has opened up new perspectives and helped to elucidate the pathogenesis of autoimmune disorders.</description><subject>Amino Acid Sequence</subject><subject>anti-RNP</subject><subject>Anti-Sm</subject><subject>Antibodies, Antinuclear - analysis</subject><subject>Antibodies, Antinuclear - biosynthesis</subject><subject>Antibody Specificity</subject><subject>autoantibodies</subject><subject>Autoantigens</subject><subject>Epstein-Barr virus</subject><subject>Humans</subject><subject>Immunoassay</subject><subject>Lupus Erythematosus, Systemic - immunology</subject><subject>Lupus Nephritis - immunology</subject><subject>Molecular Sequence Data</subject><subject>Ribonucleoproteins, Small Nuclear - chemistry</subject><subject>Ribonucleoproteins, Small Nuclear - genetics</subject><subject>Ribonucleoproteins, Small Nuclear - immunology</subject><subject>snRNP Core Proteins</subject><subject>systemic lupus</subject><issn>0891-6934</issn><issn>1607-842X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkFtLAzEQhYMotlZ_gC_qk2-rk90km0VfSvEGouIFfAvZXOiW3U1NdpH-e1NbEBHqwzAzzHcOw0HoEMMZBg7nwAvMigwIAKRpjukWGmIGecJJ-r6Nhst7EgEyQHshzJZUzsguGmDKgeRAh-h43HZV8tKcyFbHivPzw9P3UDpdmbCPdqysgzlY9xF6u756ndwm9483d5PxfaJIRruEaUWZVVAoTakFS3RuCJUKUoOxjBfOcyaVKq1KQZeZBG0x1nHlkForsxE6XfnOvfvoTehEUwVl6lq2xvVBsJwVjKX8XxDnHAODLIJ4BSrvQvDGirmvGukXAoNYxif-xBc1R2vzvmyM_lGs84rA5QqoWut8Iz-dr7Xo5KJ23nrZqiqIbJP_xS_51Mi6myrpjZi53rcx4Q3ffQF6GY5g</recordid><startdate>200502</startdate><enddate>200502</enddate><creator>Migliorini, P.</creator><creator>Baldini, C.</creator><creator>Rocchi, V.</creator><creator>Bombardieri, S.</creator><general>Informa UK Ltd</general><general>Taylor &amp; Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200502</creationdate><title>Anti-Sm and anti-RNP antibodies</title><author>Migliorini, P. ; Baldini, C. ; Rocchi, V. ; Bombardieri, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435t-6dc56fc09cd55f0f4d7e45ac02e11a6fc8876accbfc20db3a0df11dbfc802ffa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Amino Acid Sequence</topic><topic>anti-RNP</topic><topic>Anti-Sm</topic><topic>Antibodies, Antinuclear - analysis</topic><topic>Antibodies, Antinuclear - biosynthesis</topic><topic>Antibody Specificity</topic><topic>autoantibodies</topic><topic>Autoantigens</topic><topic>Epstein-Barr virus</topic><topic>Humans</topic><topic>Immunoassay</topic><topic>Lupus Erythematosus, Systemic - immunology</topic><topic>Lupus Nephritis - immunology</topic><topic>Molecular Sequence Data</topic><topic>Ribonucleoproteins, Small Nuclear - chemistry</topic><topic>Ribonucleoproteins, Small Nuclear - genetics</topic><topic>Ribonucleoproteins, Small Nuclear - immunology</topic><topic>snRNP Core Proteins</topic><topic>systemic lupus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Migliorini, P.</creatorcontrib><creatorcontrib>Baldini, C.</creatorcontrib><creatorcontrib>Rocchi, V.</creatorcontrib><creatorcontrib>Bombardieri, S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Autoimmunity (Chur, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Migliorini, P.</au><au>Baldini, C.</au><au>Rocchi, V.</au><au>Bombardieri, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-Sm and anti-RNP antibodies</atitle><jtitle>Autoimmunity (Chur, Switzerland)</jtitle><addtitle>Autoimmunity</addtitle><date>2005-02</date><risdate>2005</risdate><volume>38</volume><issue>1</issue><spage>47</spage><epage>54</epage><pages>47-54</pages><issn>0891-6934</issn><eissn>1607-842X</eissn><abstract>Among anti-nuclear antibodies, anti-Sm and anti-RNP antibodies are of the utmost importance in clinical practice. Anti-Sm antibodies are directed against 7 proteins (B/B′, D1, D2, D3, E, F, G) that constitute the common core of U1, U2, U4 and U5 small nuclear ribonucleoprotein (snRNP) particles; B/B′, D1 and D3 are more frequently targeted. Anti-RNP antibodies react with proteins (70 Kd, A, C) that are associated with U1 RNA and form U1snRNP. Anti-Sm and anti-RNP antibodies are directed towards both discontinuous and linear epitopes which are either contained in the protein sequence or are post-translationally modified. The assays to detect anti-Sm and anti-RNP antibodies are counterimmunoelectrophoresis (CIE), immunoblot, and ELISA, based on purified or recombinant proteins or synthetic peptides. Anti-Sm antibodies are detectable in a percentage of SLE patients comprised between 5 and 30%; they are more prevalent in blacks and because of their high specificity for SLE have been included in the serological criteria for diagnosing the disease. Anti-RNP are detectable in 25-47% of SLE patients; high titers of anti-RNP antibodies are diagnostic of mixed connective tissue disorder (MCTD). The measurement of anti-Sm and anti-RNP antibodies is more important in the diagnosis of SLE than in the follow-up of patients. However, anti-RNP antibodies are more prevalent in patients with Raynaud's phenomenon and are associated with milder renal involvement. On the contrary, anti-Sm antibodies are associated with the severity and the activity of renal involvement. The specificity of anti-Sm antibodies, together with epidemiological data, suggest that Epstein-Barr virus infection has the potential to induce anti-Sm antibodies by molecular mimicry. Anti-nuclear antibodies, a hallmark of the systemic autoimmune diseases, include several populations of antibodies with different specificities. Among them, anti-Sm and anti-RNP antibodies are of the utmost importance in clinical practice; in research, the study of the mechanisms inducing their production has opened up new perspectives and helped to elucidate the pathogenesis of autoimmune disorders.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>15804705</pmid><doi>10.1080/08916930400022715</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0891-6934
ispartof Autoimmunity (Chur, Switzerland), 2005-02, Vol.38 (1), p.47-54
issn 0891-6934
1607-842X
language eng
recordid cdi_pubmed_primary_15804705
source MEDLINE; Taylor & Francis Journals Complete
subjects Amino Acid Sequence
anti-RNP
Anti-Sm
Antibodies, Antinuclear - analysis
Antibodies, Antinuclear - biosynthesis
Antibody Specificity
autoantibodies
Autoantigens
Epstein-Barr virus
Humans
Immunoassay
Lupus Erythematosus, Systemic - immunology
Lupus Nephritis - immunology
Molecular Sequence Data
Ribonucleoproteins, Small Nuclear - chemistry
Ribonucleoproteins, Small Nuclear - genetics
Ribonucleoproteins, Small Nuclear - immunology
snRNP Core Proteins
systemic lupus
title Anti-Sm and anti-RNP antibodies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T08%3A05%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-Sm%20and%20anti-RNP%20antibodies&rft.jtitle=Autoimmunity%20(Chur,%20Switzerland)&rft.au=Migliorini,%20P.&rft.date=2005-02&rft.volume=38&rft.issue=1&rft.spage=47&rft.epage=54&rft.pages=47-54&rft.issn=0891-6934&rft.eissn=1607-842X&rft_id=info:doi/10.1080/08916930400022715&rft_dat=%3Cproquest_pubme%3E17810603%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17810603&rft_id=info:pmid/15804705&rfr_iscdi=true